Replies to post #630060 on NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

Bio, thanks for correcting me but I could have sworn that this unpublished graph from earlier this year



included pembrolizumab (not by name but as "PD-1 Mab") with poly-ICLC as additions to DCVax-L.
If I have totally misunderstood the nomenclature I would appreciate being corrected so that I don't dig myself into a deeper hole in the future.

Many thanks.

[The Danish Dude]

From the Al Musella webinar with Linda Liau.

Al Musella 33:57
You talked about ATL-DC at the new trials. Is that the same as DCVax?

Linda Liau:
Uhm, well yeah ... DCVax is a trade name that is actually licensed by NWBO.... So yes, we developed DCVax at UCLA."

And, interim results from the SPORE 1 project Keytruda+DCVax-L combo trial, shown in the same webinar presentation,

>65% efficacy with Keytruda+DCvax-L



Also tweeted by Allen Turner

Impressive LCM strategy before initial approval! #dcvax $nwbo

DCVax-L + Poly-ICLC. Est primary completion Jan 2024. Unpublished interim results: ~50% survival at >8 YEARS.

DCVax-L + PD-1. Est primary completion Aug 2024. Unpublished interim results: ~65% survival at >26 mos. pic.twitter.com/T0jAwH65Uo

— Allen Turner (@AllenTurner206) February 15, 2023

And the Q&A slide

[learningcurve2020]

Clearly the L trial data is taking a backseat here now. Future combos is where it's at! See how that works, folks.